ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,566Medicare Part D Prescriptions Filled, Including Refills

Rank: 258 out of 2680

$447K Total Retail Price of All Prescriptions

Rank: 459 out of 2680

292 Patients Receiving at Least One Drug in Part D
66%Patients 65 Years and Older
97% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

11% of this provider’s 292 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

3% of this provider’s 6,049 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

31% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$52 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

29 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
ZOLPIDEM TARTRATE 505 320 1 17
IBUPROFEN 343 221 2 63
SIMVASTATIN 302 212 3 1
AMLODIPINE BESYLATE 297 199 4 3
METFORMIN HCL 261 186 5 6
HYDROCHLOROTHIAZIDE 183 110 6 9
NEXIUM 178 119 7 19
LISINOPRIL 175 137 8 5
OMEPRAZOLE 160 116 9 2
PROAIR HFA 159 94 10 52
METOPROLOL TARTRATE 144 99 11 8
RANITIDINE HCL 140 112 12 35
FUROSEMIDE 138 108 13 7
CRESTOR 137 111 14 15
VENTOLIN HFA 129 72 15 61
ALENDRONATE SODIUM 119 109 16 20
ATORVASTATIN CALCIUM 119 76 16 10
NAPROXEN 116 71 18 91
JANUVIA 114 77 19 34
LEVOTHYROXINE SODIUM 103 93 20 4
ATENOLOL 101 71 21 14
CLOTRIMAZOLE-BETAMETHASONE 101 72 21 109
DIOVAN 92 79 23 26
HYDROCODONE-ACETAMINOPHEN 92 48 S3 23 13
AMOXICILLIN 91 65 25 142
GLYBURIDE 87 80 R 26 66
LOSARTAN POTASSIUM 86 76 27 18
DIOVAN HCT 80 80 28 54
FLUTICASONE PROPIONATE 80 44 28 38
METOPROLOL SUCCINATE 78 56 30 11
CLOPIDOGREL 77 54 31 30
SINGULAIR 76 53 32 64
METHOCARBAMOL 72 27 R 33 342
MELOXICAM 67 64 34 50
ADVAIR DISKUS 66 21 35 32
ENALAPRIL MALEATE 66 49 35 24
MOMETASONE FUROATE 64 56 37 245
GABAPENTIN 63 50 38 21
NEOMYCIN-POLYMYXIN-HYDROCORT 62 43 39 511
PENICILLIN V POTASSIUM 60 42 40 520
LOSARTAN-HYDROCHLOROTHIAZIDE 59 39 41 46
ACTOS 59 42 41 98
TAMSULOSIN HCL 56 42 43 25
FOSINOPRIL SODIUM 56 49 43 198
ACTOPLUS MET 55 55 45 346
PLAVIX 52 42 46 41
MECLIZINE HCL 52 46 46 105
VOLTAREN 50 35 48 103
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 6, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.